%0 Journal Article %A Brooke D. Huisman %A Zheng Dai %A David K. Gifford %A Michael E. Birnbaum %T A high-throughput yeast display approach to profile pathogen proteomes for MHC-II binding %D 2022 %R 10.1101/2022.02.22.480950 %J bioRxiv %P 2022.02.22.480950 %X T cells play a critical role in the adaptive immune response, recognizing peptide antigens presented on the cell surface by Major Histocompatibility Complex (MHC) proteins. While assessing peptides for MHC binding is an important component of probing these interactions, traditional assays for testing peptides of interest for MHC binding are limited in throughput. Here we present a yeast display-based platform for assessing the binding of tens of thousands of user-defined peptides in a high throughput manner. We apply this approach to assess a tiled library covering the SARS-CoV-2 proteome and four dengue virus serotypes for binding to human class II MHCs, including HLA-DR401, -DR402, and -DR404. This approach identifies binders missed by computational prediction, highlighting the potential for systemic computational errors given even state-of-the-art training data, and underlines design considerations for epitope identification experiments. This platform serves as a framework for examining relationships between viral conservation and MHC binding, and can be used to identify potentially high-interest peptide binders from viral proteins. These results demonstrate the utility of this approach for determining high-confidence peptide-MHC binding.Competing Interest StatementD.K.G. is a founder of ThinkTx. M.E.B. is an equity holder in 3T Biosciences, and is a co-founder of Viralogic Therapeutics and Abata Therapeutics. The other authors declare no competing interests. %U https://www.biorxiv.org/content/biorxiv/early/2022/03/11/2022.02.22.480950.full.pdf